产品说明书

Moxidectin

Print
Chemical Structure| 113507-06-5 同义名 : 莫昔克丁 ;CL301423;Milbemycin B;Vetdectin Oral Drench;Quest (parasiticide);Quest;ProHeart 6;Equest;Cydectin;23-Methoxime-LL-F 28249α
CAS号 : 113507-06-5
货号 : A109257
分子式 : C37H53NO8
纯度 : 98%
分子量 : 639.819
MDL号 : MFCD00866560
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(164.11 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Moxidectin is an anthelmintic drug which kills parasitic worms (helminths), and is used for the prevention and control of heartworm and intestinal worms. Usually when parasite populations are ML-resistant (Macrocyclic lactone), MOX (Moxidectin) is more effective than avermectins. MOX may have higher intrinsic potency against some parasites, especially filarial nematodes, than the avermectins[3]. Moxidectin is routinely used to treat gastrointestinal nematode infections and prevent heartworm disease caused by Dirofilaria immitis. Concurrent topical administration of a fluralaner plus moxidectin and a praziquantel product did not result in adverse findings. The concurrent treatment of cats with fluralaner plus moxidectin and praziquantel at the maximum dose in clinical use was well tolerated[4]. Increasing both the dose and the number of dosages of moxidectin improved efficacy, with 100% protection obtained using three dosages of moxidectin at either 40 µg/kg (JYD-34, ZoeMO) or 60 µg/kg (ZoeLA). Three dosages of 24 µg/kg were also highly effective, providing ≥ 98.8% efficacy for all three strains[5]. A single topical application of the fixed combination of fluralaner plus moxidectin to cats reduced the mean mite counts by 100%. Single topical application of the fixed combination of fluralaner plus moxidectin was highly effective against O. cynotis infestations in cats[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00751764 Infection Phase 1 Completed - United Kingdom ... 展开 >> Plymouth, United Kingdom, PL6 5HH 收起 <<
NCT03501251 Trichuris Trichiura; Infection Phase 2 Completed - Tanzania ... 展开 >> Public Health Laboratory Ivo de Carneri, P.O. Box 122 Chake Chake, Pemba, Tanzania 收起 <<
NCT00736697 Infection Phase 1 Completed - France ... 展开 >> Poitiers, France, 86000 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.56mL

0.31mL

0.16mL

7.81mL

1.56mL

0.78mL

15.63mL

3.13mL

1.56mL
参考文献

[1]Turner HC, Walker M, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015 Mar 19;8:167.

[2]Sutherland IA, Leathwick DM, Brown AE. Moxidectin: persistence and efficacy against drug-resistant Ostertagia circumcincta. J Vet Pharmacol Ther. 1999 Feb;22(1):2-5.

[3]Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69‐83

[4]Walther FM, Fisara P, Roepke RKA. Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats. Parasit Vectors. 2018;11(1):597. Published 2018 Nov 19

[5]McTier TL, Six RH, Pullins A, et al. Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs. Parasit Vectors. 2019;12(1):444. Published 2019 Sep 11

[6]Taenzler J, de Vos C, Roepke RKA, Heckeroth AR. Efficacy of fluralaner plus moxidectin (Bravecto® Plus spot-on solution for cats) against Otodectes cynotis infestations in cats. Parasit Vectors. 2018;11(1):595. Published 2018 Nov 19